Digitalis Ventures

Digitalis Ventures is a New York-based venture capital firm dedicated to investing in solutions for complex challenges across human and animal health. The firm's investment strategy is highly focused on early-stage companies, typically Seed to Series A, that leverage cutting-edge science and technology to drive significant advancements in healthcare. Digitalis emphasizes a deep understanding of scientific innovation, often backing companies at the intersection of biology, data science, and engineering. Their portfolio spans various sub-sectors within health, including therapeutics, diagnostics, digital health, and health-related technologies for animals, reflecting a broad yet specialized approach to health innovation.

The firm is known for its hands-on approach, providing not just capital but also strategic guidance and operational support to its portfolio companies. Digitalis often partners with academic institutions and leading research centers, identifying promising technologies emerging from labs and helping translate them into viable commercial ventures. This collaborative model underscores their commitment to fostering groundbreaking scientific discoveries and bringing them to market effectively. Their investments are characterized by a long-term perspective, aiming to support companies through multiple stages of growth as they navigate the complex regulatory and commercial landscapes of the health sector.

Digitalis Ventures has demonstrated a consistent track record in the health tech space, with a portfolio that includes companies like Recursion Pharmaceuticals, which went public with a valuation of over $3 billion, and numerous other successful ventures. The firm typically participates in rounds ranging from several million to tens of millions of dollars, often as a lead or co-lead investor. For instance, they have participated in rounds where their initial check might be around $1 million for a Seed stage, scaling up to $10 million or more for a Series A, depending on the company's stage and capital requirements. Their strategic focus on early-stage, science-driven companies positions them as a key player in the evolving landscape of health innovation.